Accordingly, the tumor growth inhibition rates of the lenvatinib‐treated and TBC1D31‐knocked‐down groups were 25% and 47%, respectively, while the combined treatment group increased to 75% (Figure 7f). Here, TBC1D31 is linked to neoplasm.